



**RPG LIFE SCIENCES LIMITED**  
Unit No. 208-213, B Wing,  
Bezzola Complex,  
Sion-Trombay Road, Chembur,  
Mumbai 400071, India  
Tel: +91-22-25292152-55  
Fax: +91-22-25297423

February 01, 2023

The Manager  
Listing Department  
National Stock Exchange of India Limited  
Exchange Plaza, 5th Floor  
Plot No. C1, 'G' Block, Bandra-Kurla Complex  
Bandra (East), Mumbai 400 051.

BSE Limited  
Corporate Relationship Department Floor  
25, P.J. Towers  
Dalal Street  
Mumbai 400 001.

**Symbol: RPGLIFE**

**Scrip code: 532983**

Dear Sir/Madam,

**Sub: Outcome of Board Meeting of the Company held on February 01,2023**

In terms of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company has at its meeting held on Wednesday, February 01, 2023, *inter-alia*, considered and approved the Unaudited Financial Results of the Company for the quarter and nine months ended December 31, 2022.

The said Unaudited Financial Results along with Limited Review Report of the Statutory Auditors thereon are enclosed herewith in terms of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The meeting commenced at 03:00 p.m. and concluded at 5.15 p.m.

Kindly take the above on record.

Thanking you,

Yours faithfully,  
For RPG Life Sciences Limited

RAJESH  
RAMESH  
SHIRAMBEKAR

Digitally signed by RAJESH  
RAMESH SHIRAMBEKAR  
Date: 2023.02.01 17:24:13  
+05'30'




Rajesh Shirambekar  
Head – Legal & Company Secretary

**Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
RPG Life Sciences Limited**

1. We have reviewed the accompanying statement of unaudited financial results of RPG Life Sciences Limited (the "Company") for the quarter ended December 31, 2022 and year to date from April 01, 2022, to December 31, 2022 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The comparative Ind AS financial information of the Company for the corresponding quarter and period ended December 31, 2021, included in these Ind AS financial results, were reviewed by the predecessor auditor and the Ind AS financial statements of the Company for the year ended March 31, 2022, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those financial information on January 25, 2022 and April 29, 2022 respectively.

For S R B C & CO LLP  
Chartered Accountants  
ICAI Firm registration number: 324982E/E300003



per Aruna Kumaraswamy  
Partner  
Membership No.: 219350  
UDIN: 23219350BGXWHF7429  
Place: Mumbai  
Date: February 1, 2023



STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2022

(Rs. in Lakhs)

Particulars	Quarter ended			Nine months ended		Year ended
	31-12-2022	30-09-2022	31-12-2021	31-12-2022	31-12-2021	31-03-2022
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from Operations	13,060	13,479	11,558	39,432	33,636	44,016
2 Other Income	51	123	61	296	173	299
3 <b>Total Income (1+2)</b>	<b>13,111</b>	<b>13,602</b>	<b>11,619</b>	<b>39,728</b>	<b>33,809</b>	<b>44,315</b>
4 <b>Expenses</b>						
(a) Cost of Materials Consumed	2,026	2,218	2,526	6,370	6,512	8,813
(b) Purchases of Stock-in-Trade	2,539	2,628	2,530	7,179	6,231	7,890
(c) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(318)	(309)	(1,433)	(411)	(2,182)	(2,521)
(d) Employee Benefits Expense	2,829	2,792	2,556	8,329	7,493	9,997
(e) Finance Costs	7	8	16	26	46	52
(f) Depreciation and Amortisation Expense	391	387	393	1,161	1,188	1,566
(g) Other Expenses	3,063	3,177	2,969	9,287	8,297	11,201
<b>Total Expenses</b>	<b>10,537</b>	<b>10,901</b>	<b>9,557</b>	<b>31,941</b>	<b>27,585</b>	<b>36,998</b>
5 <b>Profit before tax (3-4)</b>	<b>2,574</b>	<b>2,701</b>	<b>2,062</b>	<b>7,787</b>	<b>6,224</b>	<b>7,317</b>
6 <b>Income tax expenses</b>						
(a) Current Tax	692	716	618	2,066	1,866	2,276
(b) Deferred Tax	(29)	(12)	(19)	(8)	(38)	(107)
7 <b>Profit for the period (5-6)</b>	<b>1,911</b>	<b>1,997</b>	<b>1,463</b>	<b>5,729</b>	<b>4,396</b>	<b>5,148</b>
8 <b>Other Comprehensive Income</b>						
(a) Items that will not be reclassified to Profit or Loss	(9)	(9)	(4)	(27)	(12)	(36)
(b) Income tax relating to items that will not be reclassified to Profit or Loss	3	3	1	7	3	11
<b>Other Comprehensive Income Net of Tax</b>	<b>(6)</b>	<b>(6)</b>	<b>(3)</b>	<b>(20)</b>	<b>(9)</b>	<b>(25)</b>
9 <b>Total Comprehensive Income for the period (7+8)</b>	<b>1,905</b>	<b>1,991</b>	<b>1,460</b>	<b>5,709</b>	<b>4,387</b>	<b>5,123</b>
10 Paid-up Equity Share Capital (Face Value Rs. 8/- each)	1,323	1,323	1,323	1,323	1,323	1,323
11 Other Equity						24,254
12 <b>Earnings per Share (of Rs. 8/- each) (not annualised for the quarter):</b>						
(a) Basic (in Rs.)	11.56	12.08	8.85	34.64	26.58	31.13
(b) Diluted (in Rs.)	11.56	12.08	8.85	34.64	26.58	31.13

Notes:


- The above Unaudited Financial Results have been reviewed and recommended by the Audit Committee and have been approved by the Board of Directors at their respective meetings held on February 01, 2023.
- The Company operates in only one reportable business segment i.e. Pharmaceuticals.
- During the quarter ended 30th June 2022, the Company exercised the option of lower tax rate under section 115 BAA of Income Tax Act, 1961 as introduced by the Taxation Laws (Amendment) Act, 2019 effective April 01, 2022. Accordingly, the Company has adopted the new tax rate of 25.17% which has resulted in a reversal of deferred tax balances of Rs 46 lakhs on account of remeasurement of deferred tax balances as at 31st March, 2022 and was recognised in the quarter ended June 30 2022.
- Previous period's figures have been regrouped/reclassified wherever necessary.

SIGNED FOR IDENTIFICATION  
 BY  
  
 S R B C & CO LLP  
 MUMBAI

For RPG Life Sciences Limited



Yugal Sikri  
 Managing Director  
 DIN: 02158397  
 Mumbai, February 01, 2023



An  RPG Company